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ABSTRACT
Background. Information on lipid abnormalities in end-stage
renal disease (ESRD) mainly originates from adult patients
and small paediatric studies. We describe the prevalence of
dyslipidaemia, and potential determinants associated with
lipid measures in a large cohort of paediatric ESRD patients.
Methods. In the ESPN/ERA-EDTA registry, lipid measure-
ments were available for 976 patients aged 2–17 years from
19 different countries from the year 2000 onwards. Dyslipidae-
mia was deﬁned as triglycerides >100 mg/dL (2–9 years) or
>130 mg/dL (9–17 years), high-density lipoprotein (HDL)
cholesterol <40 mg/dL or non-HDL cholesterol >145 mg/dL.
Missing data were supplemented using multiple imputation.
Results. The prevalence of dyslipidaemia was 85.1% in perito-
neal dialysis (PD) patients, 76.1% in haemodialysis (HD) patients
and 55.5% among renal allograft recipients. Both low and high
body mass index (BMI) were associated with a less favourable
lipid proﬁle. Younger age was associated with a worse lipid
proﬁle among PD patients. HDL levels signiﬁcantly improved
after transplantation, whereas no signiﬁcant improvements
were found for triglyceride and non-HDL levels. In transplant
recipients, use of cyclosporin was associated with signiﬁcantly
higher non-HDL and HDL levels than tacrolimus usage
(P < 0.01). In transplant patients with eGFR < 29 mL/min/
1.73 m2, the mean triglyceride level was 137 mg/dL (99% con-
ﬁdence interval (CI): 119–159) compared with 102 mg/dL
among those with eGFR > 90 mL/min/1.73 m2 (P < 0.0001).
Conclusions. Dyslipidaemia is common among paediatric
ESRD patients in Europe. Young age and PD treatment are
associated with worse lipid proﬁles. Although lipid levels gen-
erally improve after transplantation, dyslipidaemia may persist
due to decreased graft function, high BMI or to the use of
certain immunosuppressants.
© The Author 2013. Published by Oxford University Press on
behalf of ERA-EDTA. All rights reserved.
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INTRODUCTION
Cardiovascular disease is a major cause of morbidity and
mortality in children with end-stage renal disease (ESRD) [1].
Paediatric dialysis patients are estimated to have an up to
1000-fold increased cardiovascular mortality risk compared
with age-related peers [2]. Dyslipidaemia has been reported in
over 50% of paediatric ESRD patients [1, 3]. Insulin resistance,
increased Apo lipoprotein C-III and impaired lipolysis [4, 5]
are involved in the inappropriate clearance of lipoproteins,
contributing to lipid abnormalities in the uraemic environ-
ment [4]. Whereas neither peritoneal dialysis (PD) nor
haemodialysis (HD) fully correct the lipoprotein abnormal-
ities, these treatment modalities appear to have differential
effects on lipid levels, with PD generally causing a less favour-
able lipid proﬁle than HD [6]. Although transplantation
corrects the uraemic environment, transplanted patients still
display a high rate of dyslipidaemia [1], mainly due to the
chronic use of immunosuppressive medications [7].
Since dyslipidaemia is a potentially modiﬁable risk
factor, and in the general population, childhood lipid levels
were found to persist into adulthood and predict cardiovas-
cular disease in later life [8], it is important to identify the
factors associated with dyslipidaemia in paediatric ESRD.
Most data regarding dyslipidaemia in paediatric ESRD orig-
inate from cross-sectional single-centre studies [3, 9–11],
and information about the change of lipid levels over time
is scarce [12]. Therefore, the objective of this study is to
describe the prevalence and evolution of dyslipidaemia and
its potential determinants in a large cohort of paediatric
ESRD patients.
MATERIALS AND METHODS
Subjects
The ESPN/ERA-EDTA registry collects annual data of
paediatric patients undergoing renal replacement therapy
(RRT) in Europe. Within the registry, individual patient
data are collected regarding date of birth, gender, primary
renal diagnosis, the initial and any subsequent RRT treat-
ment modalities, as well as a variable set of anthropometric,
biochemical and medication-related data. For the present
study, only those countries providing data on total choles-
terol, high-density lipoprotein (HDL) cholesterol and trigly-
ceride levels from the year 2000 onwards were included.
This included information for the following countries and
periods: Belarus (2008–10), Czech Republic (2007–11),
Denmark (2008), Estonia (2008–10), Finland (2000–10),
Greece (2009–12), Croatia (2009), Hungary (2005–11),
Iceland (2005–11), Lithuania (2008–12), FYR Macedonia
(2008–12), Norway (2008–10), Poland (2007–12), Portugal
(2007–11), Serbia (2007–12), Slovakia (2005–10), Slovenia
(2007–10), Switzerland (2009) and the Netherlands (2007–
12). Missing data for total cholesterol (3.4%), HDL (31.6%),
triglycerides (14.3%), serum creatinine (16.7%), height
(8.3%) and weight (7.9%) were imputed using a multiple
imputation method as recommended by the STROBE guide-
lines [13, 14]. To test whether associations were similar in
patients with complete information we performed sensitivity
analyses among complete cases only, these analyses did not
reveal different associations compared with the associations
found in patients in whom missing data were imputed.
Deﬁnition of variables
Non-HDL cholesterol was calculated as total cholesterol-
HDL cholesterol. We deﬁned dyslipidaemia by the presence
of at least one of the following: hypertriglyceridaemia (trigly-
cerides >100 mg/dL (>1.1 mmol/L) (2–9 years of age) or tri-
glycerides >130 mg/dL (>1.5 mmol/L) (10–17 years of age)),
low HDL cholesterol (<40 mg/dL or <1.0 mmol/L) or high
non-HDL cholesterol (>145 mg/dL or >3.7 mmol/L) accord-
ing to the guidelines for cardiovascular health and risk
reduction in children and adolescents [15]. The eGFR was
calculated using the new Schwartz formula [16]. To reﬂect
changes in body size and adiposity during childhood, the
body mass index (BMI) is expressed in age and sex speciﬁc
values. However, as paediatric ESRD patients usually suffer
from growth retardation, it has been suggested to express
their BMI according to height age (age at which a child’s
height will be at the 50th percentile) [17]. Therefore, BMI was
calculated as weight/height2 and expressed to height age. We
used cut-off values of the International Obesity Task Force
[18, 19] to categorize BMI. To study the effects of a continu-
ous measure for BMI on lipid levels, we modelled BMI as the
percent difference from the median BMI (BMI%) [20] ac-
cording to WHO growth charts [21]. Associations between
BMI and lipid measures did not differ when BMI was ex-
pressed relative to chronological age instead of according to a
patient’s height age.
Statistical analyses
The number of lipid measurements recorded in the registry
differed largely per patient. To correct for the correlations of
measurements within the same patient, we used multinomial
generalized estimating equations models [22] to estimate
prevalence estimates of dyslipidaemia. In this way, a patient
who had an elevated triglyceride level at one measurement and
a normal triglyceride level at the second measurement, this
patient contributed as ½ of a patient to the group of patients
with elevated triglyceride levels and ½ to the group with
normal triglyceride levels. To study factors associated with
different lipid levels, lipid concentrations were log transformed
and analysed with linear mixed models with both a random
intercept and a random slope to account for the time between
successive measurements within a patient, and adjustments
were made for possible confounders. We adjusted the P-value
for multiple testing by using a more conservative cut-off value
for signiﬁcance. P-values of <0.01 were considered statistically
signiﬁcant, and results are presented with 99% CIs. All statisti-
cal analyses were performed in SAS version 9.2 (SAS Institute
Inc., Cary, NC).
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RESULTS
Patient characteristics
For a total of 976 patients, information on lipid levels was
available from 3293 measurements (median 5, range of 1–27
measurements per patient). Patient characteristics are listed in
Table 1. At the time of lipid measurement, most patients
(54.7%) were between 12 and 17 years of age, 58.2% of the
patients were male, 52.7% had a functioning graft and the
most common cause of renal failure was CAKUT (38.1%).
Prevalence of dyslipidaemia
The prevalence of dyslipidaemia in the total cohort was
68.0%. No signiﬁcant country differences were found, except
for PD patients from Portugal who displayed a signiﬁcantly
lower prevalence of dyslipidaemia. In Figure 1, the prevalence
of dyslipidaemia is shown stratiﬁed by lipid marker and treat-
ment modality. The prevalence of dyslipidaemia was highest
among PD patients (85.1%) and lowest among transplant reci-
pients (55.5%), while 76.1% of the HD patients suffered from
dyslipidaemia (P < 0.0001). Of the different lipid measures, tri-
glyceride levels were most frequently abnormal; hypertrigly-
ceridaemia was found among 73.9% of PD, 60.7% of HD and
45.3% of the patients with a functioning graft (P < 0.0001).
Low HDL cholesterol levels were found in 23.8% of PD, 38.2%
of HD patients and 12.9% of transplant patients, whereas elev-
ated non-HDL levels were found in 54.6% of PD patients,
24.1% of HD patients and 22.5% of the transplant recipients.
Among the patients with dyslipidaemia, 33.7% displayed com-
bined dyslipidaemia (i.e. more than one lipid abnormality)
and combined dyslipidaemia was more common among dialy-
sis patients (39.1% in HD and 55.4% in PD) as compared with
transplant recipients (23.4%) (P < 0.0001).
Modelled association between body mass index
and lipid levels
Both a low and a high BMI were associated with a less
favourable lipid proﬁle (Figure 2). After adjustment for age,
sex and treatment modality, we found a U-shaped association
between BMI and triglyceride and non-HDL levels, whereas
BMI and HDL cholesterol were associated in an inverted-U-
shaped manner. Due to a limited number of dialysis patients
in the overweight group and transplant patients in the under-
weight group, the increased risk of dyslipidaemia in under-
weight patients was mainly seen in dialysis patients and the
association between being overweight and dyslipidaemia was
most apparent in the transplant recipients.
Mean lipid levels in HD patients
All mean lipid levels were lower in patients on HD (N = 236)
(triglycerides: 139 mg/dL (124–155), non-HDL: 111 mg/dL
(103–121) and HDL: 43.8 mg/dL (40.9–46.8)) (Table 2), as
compared with patients on PD (triglycerides: 174 mg/dL, non-
HDL: 144 mg/dL, HDL: 48.8 mg/dL) (Table 3). There were no
age and gender differences between the lipid levels of HD
patients, and HD vintage was not associated with any of the
lipid measures (Table 2). Furthermore, hypoalbuminaemic HD
patients tended to have higher triglyceride (152 mg/dL, 99%
CI: 128–180 mg/dL) and non-HDL levels (119 mg/dL, 99% CI:
107–132 mg/dL) compared with patients with normal albumin
Table 1. Patient characteristics of prevalent
patients
Patients (N = 976)
Age at start of RRT (years) N (%)
0–1 224 (23.0)
2–5 182 (18.7)
6–11 296 (30.3)
12–17 274 (28.0)
Age at lipid measurement (years)
2–5 176 (18.0)
6–11 266 (27.3)
12–17 534 (54.7)
Gender (%)
Male 568 (58.2)
Female 408 (41.8)
Treatment modality at start of RRT
HD 281 (28.8)
PD 604 (61.9)
Tx 84 (8.6)
Unknown/missing 7 (0.7)
Treatment modality at lipid measurement
HD 178 (18.2)
PD 284 (29.1)
Tx 514 (52.7)
Primary renal disease
CAKUT 372 (38.1)
Glomerulonephritis 146 (15.0)
Cystic kidneys 121 (12.4)
Hereditary nephropathy 132 (13.5)
Ischaemic renal failure 20 (2.0)
HUS 35 (3.6)
Metabolic disorders 23 (2.4)
Vasculitis 7 (0.7)
Miscellaneous 78 (8.0)
Unknown/missing 42 (4.3)
RRT, renal replacement therapy; HD, haemodialysis; PD,
peritoneal dialysis; Tx, renal transplant; CAKUT, congenital
anomalies of the kidney and the urinary tract; HUS, haemolytic-
uraemic syndrome.
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levels, for whom triglyceride and non-HDL levels were 134
and 108 mg/dL, respectively, but these results did not differ
signiﬁcantly.
Mean lipid levels in PD patients
Mean lipid levels differed according to subgroups of PD
patients (N = 365) (Table 3). Triglyceride and non-HDL levels
were inversely associated with age: younger patients displayed
signiﬁcantly higher triglyceride and non-HDL levels. Gender,
time on PD and hypoalbuminaemia were not associated with
any of the lipid levels in PD patients.
Mean lipid levels in transplant recipients
Among transplant recipients (N = 564), average triglycer-
ide, non-HDL and HDL levels were 116, 115 and 54.6 mg/dL,
respectively. Associations of potential risk factors and lipid
levels among transplanted patients are listed in Table 4. The
use of cyclosporin instead of tacrolimus resulted in signiﬁ-
cantly higher triglyceride, non-HDL and HDL levels. Steroid
use tended to be associated with higher triglyceride and non-
HDL levels. The use of mycophenolate mofetil (MMF) instead
of azathioprine was associated with signiﬁcantly lower HDL
F IGURE 1 : Prevalence of dyslipidaemia by lipid marker stratiﬁed by treatment modality (TG, triglycerides; HDL, HDL cholesterol; non-HDL,
non-HDL cholesterol).
F IGURE 2 : Modelled association between BMI% and lipid levels. Adjustments were made for age, sex and treatment modality. BMI%
was calculated as the percentage difference from the median BMI-for-age based on BMI curves from the World Health Organization [21].
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levels, while triglyceride levels were signiﬁcantly higher when
using MMF compared with using azathioprine. Sirolimus use
was associated with higher triglyceride, non-HDL and HDL
levels, but only the latter two were signiﬁcantly higher.
Based on our modelling, we attempted to identify an immuno-
suppressive protocol which would result in the most favourable
lipid proﬁle. Patients treated with a hypothetical combination of
tacrolimus and azathioprine seemed to have the most favourable
lipid proﬁle which would result in a lower prevalence of dyslipi-
daemia (48.6%) compared with transplant patients on other im-
munosuppressive protocols (57.4%).
Finally, we found an inverse association between eGFR and
triglyceride levels. Triglyceride levels of patients with an
eGFR < 29 mL/min/1.73 m2 were on average 137 mg/dL (99%
CI: 119–159) compared with 102 mg/dL in patients with an
eGFR > 90 mL/min/1.73 m2 (P < 0.0001). However, no such
association was found for non-HDL or HDL cholesterol
(Figure 3).
Intra-individual changes in lipid levels
For a total number of 126 patients lipid levels were available
while changing from dialysis (mean time before transplantation:
5.2 months) to transplantation (mean follow-up time post-
transplant: 4.9 months). Following renal transplantation, mean
triglyceride levels showed a non-signiﬁcant decrease of 23 mg/dL
(99% CI: −56 to 9 mg/dL, P = 0.06), while average HDL levels
Table 2. Factors associated with mean lipid levels in HD patients
Triglycerides (mg/dL)
Mean (99% CI)
Non-HDL (mg/dL)
Mean (99% CI)
HDL (mg/dL)
Mean (99% CI)
All HD patients (N = 236) 138.8 (124.1–155.1) 111.4 (102.8–120.7) 43.8 (40.9–46.8)
Age (years)a
2–5 146.9 (114.5–188.5) 124.8 (105.7–147.4) 43.2 (37.3–49.9)
6–11 148.2 (124.6–176.2) 110.6 (98.8–124.0) 46.9 (42.3–51.9)
12–17b 134.4 109.5 42.9
Gender
Maleb 141.1 113.0 43.6
Female 136.1 (116.8–158.5) 109.2 (97.6–122.1) 43.9 (40.0–48.2)
HD vintage (years)c
<0.5 145.3 (121.5–173.8) 117.8 (104.0–133.4) 40.0 (38.9–49.2)
0.5 < 1 128.8 (85.9–193.0) 103.9 (80.2–134.6) 51.0 (40.3–64.6)
1 < 2 116.3 (87.5–154.4) 91.5 (76.1–110.0) 39.8 (33.5–47.2)
≥2b 135.9 106.5 44.7
Primary renal diseasec
FSGS with nephrotic syndrome 146.1 (114.7–186.0) 127.8 (106.4–153.4) 41.8 (35.4–49.4)
Other causeb 145.1 115.0 44.7
BMI-for-height agec
Underweight 171.3 (124.8–235.2) 123.9 (103.7–148.0) 41.4 (34.3–50.1)
Normal weightb 136.6 109.5 45.0
Overweight 133.3 (108.5–164.0) 106.4 (94.3–120.1) 44.6 (39.1–50.8)
Obese 140.0 (104.0–188.6) 113.0 (93.5–136.4) 39.9 (33.6–47.4)
Albuminc
Low (albumin <35 g/L) 152.1 (127.9–180.8) 118.8 (107.1–131.9) 41.7 (37.8–46.1)
Normal (albumin ≥35 g/L)b 133.9 107.6 44.5
To convert values for triglycerides to mmol/L multiply by 0.0113, to convert non-HDL and HDL cholesterol to mmol/L multiply by 0.0258.
BMI, body mass index.
aAdjusted for country and sex.
bReference category.
cAdjusted for country, age and sex.
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signiﬁcantly increased by 8.6 mg/dL (99% CI: 4.4–12.8 mg/dL,
P < 0.0001). The mean change in non-HDL level following
transplantation was +7 mg/dL (99% CI: −8 to 22 mg/dL,
P = 0.24).
To put these post-transplant changes into perspective,
information on normal within-subject variation in serum lipid
levels is needed. Therefore, we selected subsequent lipid
measurements of patients who did not switch RRT treatment.
The average time between these subsequent lipid determi-
nations was 314 days. We found a large intra-individual vari-
ation between subsequent triglyceride measurements. In PD
patients (N = 180), 59% of the total variance in triglyceride
levels could be attributed to the variance within the same
patient, whereas this was 51% in HD (N = 106) and 42% in
transplant patients (N = 358). For HDL and non-HDL choles-
terol levels the intra-individual variation was slightly lower,
but still 34–53% of the total variance in HDL and 27–39% of
the total variance in non-HDL cholesterol was intra-individual
variation. There were no signiﬁcant trends in the variations of
serum lipids over time.
DISCUSSION
Over 60% of the European children with ESRD suffer from
dyslipidaemia. Its prevalence varies by treatment modality,
Table 3. Factors associated with mean lipid levels in PD patients
Triglycerides (mg/dL)
Mean (99% CI)
Non-HDL (mg/dL)
Mean (99% CI)
HDL (mg/dL)
Mean (99% CI)
All PD patients (N = 365) 173.6 (158.6–190.0) 144.3 (135.0–154.2) 48.8 (45.5–52.3)
Age (years)a
2–5 218.2 (187.3–254.2) 162.0 (148.8–176.3) 48.6 (44.4–53.2)
6–11 179.2 (156.7–205.0) 146.5 (135.4–158.5) 48.7 (44.9–52.8)
12–17b 140.1 129.5 49.0
Gender
Maleb 173.9 144.0 48.6
Female 173.9 (151.1–200.1) 145.7 (135.0–157.3) 49.0 (45.5–52.8)
Peritoneal dialysis vintage (years)c
<0.5 177.1 (146.0–215.0) 146.2 (131.0–163.1) 48.9 (43.5–54.9)
0.5 < 1 155.7 (106.9–226.7) 130.4 (106.7–159.2) 49.2 (39.5–61.3)
1 < 2 145.5 (108.4–195.3) 142.2 (121.1–167.1) 48.8 (40.8–58.4)
≥2b 152.8 136.0 47.9
Primary renal diseasec
FSGS with nephrotic syndrome 203.9 (162.8–255.4) 156.4 (142.0–173.3) 45.6 (39.8–52.4)
Other causeb 169.5 146.0 49.6
BMI-for-height agec
Underweight 187.9 (155.4–227.2) 151.4 (135.2–169.6) 47.7 (42.2–53.9)
Normal weightb 178.8 147.5 49.4
Overweight 183.5 (157.8–213.3) 139.9 (127.6–153.3) 46.2 (41.9–50.9)
Obese 185.3 (152.7–224.8) 141.3 (125.6–159.0) 50.3 (44.5–56.9)
Albuminc
Low (albumin <35 g/L) 172.3 (156.2–190.1) 146.8 (140.4–153.5) 48.5 (45.5–51.7)
Normal (albumin ≥35 g/L)b 174.9 142.8 49.0
Bold values are statistically signiﬁcant at the 0.01 level.
To convert values for triglycerides to mmol/L multiply by 0.0113, to convert non-HDL and HDL cholesterol to mmol/L multiply by 0.0258.
BMI, body mass index.
aAdjusted for country and sex.
bReference category.
cAdjusted for country, age and sex.
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Table 4. Factors associated with mean lipid levels in transplant patients
Triglycerides (mg/dL)
Mean (99% CI)
Non-HDL (mg/dL)
Mean (99% CI)
HDL (mg/dL)
Mean (99% CI)
All transplanted patients (N = 564) 116.0 (108.6–123.8) 114.7 (109.4–120.2) 54.6 (52.5–56.8)
Age (years)a
2–5 128.4 (115.9–142.3) 119.2 (110.9–128.2) 54.3 (51.2–57.6)
6–11 112.2 (104.6–120.5) 116.7 (111.1–122.6) 56.2 (54.0–58.5)
12–17b 114.8 112.8 54.0
Gender
Male 115.8 113.4 53.8
Female 116.0 (105.8–127.1) 117.1 (109.7–125.0) 55.9 (52.8–59.3)
Time on current treatment (years)c
<0.5 109.3 (97.3–122.8) 111.3 (102.4–121.0) 54.2 (50.5–58.1)
0.5 < 1 118.6 (104.1–135.2) 116.5 (106.1–128.0) 54.6 (50.5–59.0)
1 < 2 112.1 (98.2–128.0) 112.5 (102.3–123.6) 55.0 (50.8–59.5)
≥2b 123.4 118.0 52.7
Pre-emptive transplantationc
Yesb 113.3 106.5 51.6
No 116.5 (101.7–133.4) 115.9 (105.2–127.6) 54.2 (49.9–58.9)
Primary renal diseasec
FSGS with nephrotic syndrome 132.2 (106.2–164.6) 134.6 (111.4–162.6) 53.8 (46.8–61.8)
Other causeb 115.2 114.6 54.6
Calcineurin inhibitorsd
Tacrolimusb 111.6 103.0 52.0
None 112.3 (93.0–135.7) 113.9 (100.5–129.0) 53.5 (48.4–59.2)
Cyclosporin 129.4 (118.4–141.4) 125.6 (118.3–133.3) 58.4 (55.7–61.2)
Steroidsd
Yes 122.3 (109.1–137.0) 115.8 (106.4–123.8) 55.8 (52.3–59.1)
Nob 110.2 110.7 53.0
mTOR inhibitord
Nob 119.7 113.2 54.8
Sirolimus 130.9 (93.3–183.4) 152.7 (122.1–191.0) 67.4 (56.0–81.3)
Antimetabolitesd
AZAb 111.6 112.5 57.7
MMF 123.6 (113.3–134.7) 115.5 (109.0–122.4) 53.2 (50.9–55.6)
None 124.7 (110.8–140.4) 112.7 (104.2–121.8) 56.0 (52.6–59.6)
BMI-for-height agee
Underweight 101.4 (73.6–139.6) 112.5 (89.6–141.2) 54.7 (45.8–65.2)
Normal weightb 114.1 111.2 56.5
Continued
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with the highest prevalence observed in PD patients, but even
after transplantation 50% of patients display dyslipidaemia.
Our estimates were similar to those reported previously in
children with chronic renal failure: 45% in children with
chronic kidney disease (CKD) [23, 24], 56–93% in dialysis
patients [25, 26] and 15–67% among transplant recipients [3,
9, 11, 25, 27]. All these ﬁgures are much higher than those re-
ported in healthy children, which vary between ∼10% and
over 20% [28–31].
Although hypertriglyceridaemia was most frequently ob-
served in our cohort (ranging from 45.3% among transplanted
patients to 73.9% among PD patients), elevated non-HDL
cholesterol levels seemed to be most important for cardiovas-
cular disease [32, 33]. This was observed in 30.8% of the
patients.
We found that both a low and a high BMI were associated
with a less favourable lipid proﬁle for all parameters. A high
BMI has been identiﬁed as a distinct risk factor for dyslipidae-
mia in the paediatric CKD population [23, 24], the general
paediatric population [30], as well as adult renal graft recipi-
ents [34]. Moreover, a low BMI could be a marker of severity
of disease, and a reason for calorie supplementation, thereby
resulting in a less favourable lipid proﬁle.
The observed U-shaped association of BMI with dyslipidae-
mia resembles the previously reported relationship of BMI and
mortality risk in children with ESRD [35] and contrasts with
observations in adult dialysis patients [36]. Nevertheless,
although data from the Bogalusa heart study show that in the
general childhood population lipid levels persist into adult-
hood and predict cardiovascular disease in later life [8], it is
not known to what extent abnormal lipid levels are associated
with adverse outcomes in children. This would be an interest-
ing topic for future studies.
Another predictor for an abnormal lipid proﬁle in dialysis
patients was receiving PD treatment, especially among those of
young age. The high glucose load from the dialysis ﬂuid might
contribute to this high dyslipidaemia prevalence [26]. Although
it has been suggested that considerable protein losses in the dia-
lysate also contribute to the disturbed lipid proﬁle, we did not
ﬁnd higher lipid levels among hypoalbuminaemic PD patients,
which is consistent with data from a Turkish study [37]. As we
did not have sufﬁcient data on C-reactive protein levels, it was
not possible to study the effect of inﬂammation (C-reactive
protein) on serum lipid levels. Besides lower cut-off values for
hypertriglyceridaemia in children younger than 9 years of age,
the absolute triglyceride, as well as the non-HDL levels, were
higher among younger children. This may in part reﬂect a
puberty-related decrease in non-HDL levels [38]. Furthermore,
many young patients (especially those on PD) might receive
supplemental feeding [39, 40] possibly leading to higher lipid
levels. Indeed, increased (dietary) energy intake of PD patients
has been associated with higher triglyceride and cholesterol
levels [41].
In transplant recipients, both the use of cyclosporin and
glucocorticoids as immunosuppressive therapy was positively
associated with an adverse lipid proﬁle. Several other studies
have suggested that combined steroid and cyclosporin use in-
creases the risk of dyslipidaemia [9, 12, 25, 42]. The use of ta-
crolimus instead of cyclosporin has been associated with
better graft function in paediatric [42] and adult renal graft re-
cipients [43, 44]. A signiﬁcantly improved lipid proﬁle was
found after late steroid withdrawal [45], and with reducing the
use of steroids to very low doses [46]. One of the most notable
side effects of sirolimus use is a marked increase in serum lipid
levels [47]. Indeed, we found a signiﬁcant increase in non-
HDL and HDL levels associated with sirolimus use, which was
more pronounced than the effect of cyclosporine. Modiﬁ-
cation of immunosuppressive protocols might play a role in
reducing lipid abnormalities among graft recipients. Modelling
the conditions associated with the most favourable lipid
proﬁle, we found that an immunosuppressive protocol consist-
ing of tacrolimus and azathioprine would interfere least with
lipid metabolism. Furthermore, we found an inverse associ-
ation between graft function and triglyceride levels. Surpris-
ingly, we did not ﬁnd a positive association between graft
function and HDL cholesterol levels. This might partly be
explained by the low prevalence of abnormal HDL levels
among graft recipients in our population or by the use of
different immunosuppressive medications. Previous studies
among adult graft recipients reported an independent
Table 4. Continued
Triglycerides (mg/dL)
Mean (99% CI)
Non-HDL (mg/dL)
Mean (99% CI)
HDL (mg/dL)
Mean (99% CI)
Overweight 120.4 (109.3–132.6) 116.8 (109.4–124.8) 55.6 (52.9–58.5)
Obese 132.1 (116.5–149.8) 124.0 (113.8–135.1) 55.3 (51.7–59.3)
Bold values are statistically signiﬁcant at the 0.01 level.
To convert values for triglycerides to mmol/L multiply by 0.0113, to convert non-HDL and HDL cholesterol to mmol/L multiply by 0.0258.
FSGS, focal segmental glomerulosclerosis; mTOR, mammalian target of rapamycin; AZA, azathioprine; MMF, mycophenolate mofetil;
BMI, body mass index.
aAdjusted for country and sex.
bReference category.
cAdjusted for country, age, sex and year of transplantation.
dAdjusted for country, age, sex, time since transplantation, year of transplantation and eGFR.
eAdjusted for country, age, sex, year of transplantation and immunosuppressive medication.
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association between dyslipidaemia and graft loss [48, 49],
leading to the assumption that dyslipidaemia might be in-
volved in the atherosclerotic process of graft arteries. However,
a lower GFR was associated with dyslipidaemia in children
with CKD [23] and is a frequent complication among renal
transplant patients [1]. Dyslipidaemia is therefore, most likely
a consequence rather than cause of deteriorating graft func-
tion.
Similar to others [50] we found a large intra-individual
variation in serum lipid levels. Porkka et al. reported a
correlation coefﬁcient of only 0.49 between triglyceride levels
when measured 7 days apart, with similar ﬁndings for total,
HDL and LDL cholesterol [50]. As the average time between
repeated lipid measurements in our registry was much longer
than 7 days, the large intra-individual variation would mainly
result from biological variation in serum lipid levels, therefore
explaining limited changes over time. The large intra-
individual variation might also have resulted in the marginal
post-transplant improvements in the lipid proﬁle of patients
changing from dialysis to transplantation. Given the lower
prevalence of dyslipidaemia as well as a more favourable lipid
proﬁle in transplant compared with dialysis patients, we
believe that there was a true, albeit modest, improvement in
lipid levels post-transplant.
Transplantation could thus be an important step towards a
better cardiovascular risk proﬁle in paediatric ESRD patients.
Further improvement in lipid proﬁles might occur through a
diet restricted in (saturated) fat, which was found to decrease
total and LDL cholesterol levels by 11 and 14%, respectively
[51]. Statin or ﬁbrate use was not reported in our registry, but
if statins or ﬁbrates were actually applied to lower lipid levels
our ﬁndings would even underestimate the true prevalence of
dyslipidaemia. However, no studies have been performed on
statin safety and efﬁcacy in children undergoing dialysis [52],
and studies in adult dialysis patients yielded conﬂicting results
[53–56].
A limitation of our study might be the measurement of
serum lipids under non-fasting conditions.
Although it is common practice to measure blood speci-
mens after an overnight fast, this information was not reported
in our registry. Total and HDL cholesterol (and thus non-
HDL levels) can be accurately measured in plasma from non-
fasting patients [38], but considerable variation between
fasting and non-fasting lipid levels has been reported [57].
Furthermore, the use of different analytical methods for lipid
determination across participating centres might also have in-
troduced variability in the measurements [58]. However, the
potential error in lipid measurements is likely to be unrelated
to the presence of dyslipidaemia (non-differential misclassiﬁ-
cation), and will therefore, mainly have resulted in a underesti-
mation of the associations, resulting in wider CIs and less
signiﬁcant associations between lipid levels and the factors
studied. HDL cholesterol, and therefore non-HDL cholesterol,
was missing for 31.6% of patients. As patients with complete
data might have different characteristics than patients with
missing data, excluding patients with missing data might
result in biased estimates. We approached this issue by supple-
menting missing data using multiple imputation, which has
been shown to result in valid estimates [13]. Furthermore, sen-
sitivity analyses comparing the original and imputed databases
did not show any differences in associations.
Another limitation of our study is the lack of data regarding
proteinuria in renal graft recipients and residual renal function
in dialysis patients which could have affected the lipid levels
[4, 7].
In summary, dyslipidaemia is present in more than half of
paediatric ESRD patients in Europe. Lipid levels improve
but do not normalize entirely after transplantation. The PD
F IGURE 3 : Association between eGFR and mean levels of triglycer-
ides (A), non-HDL cholesterol (B) and HDL cholesterol (C). Adjust-
ments were made for age, sex, time since transplantation and year of
transplantation.
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modality and young age are key factors associated with higher
lipid levels among dialysis patients, while graft function, BMI
and immunosuppressive medications are determinants of lipid
levels among transplant patients. Considering its association
with cardiovascular morbidity and mortality, dyslipidaemia
should receive close attention in the treatment of children with
ESRD.
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